Blincyto (Blinatumomab)

What it is and what it treats

Blinatumomab is a bispecific T-cell engager (BiTE) antibody construct that binds simultaneously to CD19 on malignant B-lymphoblasts and CD3 on cytotoxic T-cells, forming a transient synapse that activates the patient's own T-cells against the leukaemic clone. This mechanism does not depend on antigen presentation through the major histocompatibility complex, which distinguishes it from conventional immunotherapies.

Regulatory authorities, including the EMA and FDA, have approved blinatumomab for Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL) in adults and children, and for consolidation in patients in haematological remission with measurable residual disease. It is used within specialist haemato-oncology centres as part of a structured treatment pathway.

Because blinatumomab redirects T-cell activity rather than delivering a cytotoxic payload directly, its use is confined to settings with the capacity to manage acute immune-related reactions, including intensive monitoring during the first days of each treatment cycle. Patient selection, staging and prior therapy are assessed by a haematologist before treatment is considered.

Presentations and dosage forms

• Powder for concentrate for solution for infusion, 38.5 micrograms per vial
• Supplied with a separate IV solution stabiliser for preparation of the infusion bag
• Single-use vial intended for continuous intravenous administration only
• Reconstitution and dilution must follow the approved preparation instructions in a controlled pharmacy environment

How it is administered

The EU SmPC describes blinatumomab as administered by continuous intravenous infusion using an infusion pump, delivered without interruption over 24 hours a day for up to 28 days per cycle, followed by a treatment-free interval, and repeated for further cycles depending on response and tolerability.

Dosing in the label is stepped: a lower dose is described for the initial days of the first cycle, increasing thereafter, in order to reduce the incidence and severity of cytokine release syndrome as the T-cell response is established. Any dose adjustment or interruption is a decision for the treating physician based on the observed clinical picture.

Initiation of each new cycle and any re-initiation after interruption is described in the label as occurring in a hospital setting, with the patient hospitalised for the first days for observation. Pre-medication with corticosteroids prior to the first dose of each cycle is part of the described regimen.

Storage and handling

• Store the sealed vials at 2–8 °C, protected from light, in the original packaging
• Do not freeze the concentrate or the stabiliser solution
• Once prepared, the infusion bag has defined stability windows at refrigerated and at room temperature described in the SmPC — preparation must respect these limits
• Transport requires validated cold-chain packaging with continuous temperature monitoring
• Discard any unused product remaining after the stated in-use period

Side effects

The following reflects adverse reactions described in the approved EU SmPC and FDA prescribing information for blinatumomab.

Commonly reported

Serious effects requiring medical attention

Blinatumomab carries boxed warnings for cytokine release syndrome and neurotoxicity. Any new or worsening neurological or systemic symptom during infusion should be reported to the treating team immediately; adverse reactions should also be reported through national pharmacovigilance schemes.

Availability and supply route

Marketing authorisation for blinatumomab and its approved indications varies by country and regulatory jurisdiction. Clinicians and procurement teams should confirm local licensing status, approved indications and reimbursement pathways with the relevant national medicines agency before planning treatment.

Where blinatumomab is not locally registered or is temporarily unavailable, hospitals may pursue supply through named-patient or unlicensed-medicine import routes, which allow a licensed pharmacy or wholesaler to source a specific, physician-prescribed product for an individual patient in accordance with national import regulations. This route always requires a valid prescription and documented clinical justification.

Pharmacy Remedy is a licensed Turkish pharmaceutical wholesaler that supplies medicines to hospitals, clinics and licensed pharmacies through verified institutional channels. It does not sell directly to members of the public and operates within the regulatory framework governing wholesale pharmaceutical distribution and named-patient supply.

Frequently asked questions

Primary sources

• EMA — Blincyto EPAR
• FDA — Blincyto prescribing information
• WHO — Model List of Essential Medicines

Further reading and regulatory routes

• Which country Blincyto is sourced from, and why prices differ
• How to verify a medicine is genuine
• Why medicines cost less in Türkiye
• WHO falsified medicine alerts
• Named patient supply
• UAE import guide
• For healthcare professionals
• All medicine monographs

Related medicines

• Kyprolis (carfilzomib)
• Keytruda (pembrolizumab)
• Opdivo (nivolumab)